Open access · US-GOV via ClinicalTrials.gov Clinical trial

Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

Authors not listed

Instituto Nacional de Cancerologia de Mexico · 2016

Epigenetic alterations Human Randomized controlled trial

Abstract

This study evaluate the association of body composition (mainly free-fat mass), clinical and biochemical parameters with development of toxicity in patients under treatment with Carboplatin/Paclitaxel in advanced NSCLC.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-23 MST

Cite this

APA

Anonymous. (2016). Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). <em>Instituto Nacional de Cancerologia de Mexico</em>. https://clinicaltrials.gov/study/NCT02734069

Vancouver

Anonymous. Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC). Instituto Nacional de Cancerologia de Mexico. 2016.

BibTeX

@misc{anon2016Impact, title = {Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)}, author = {Anonymous}, journal = {Instituto Nacional de Cancerologia de Mexico}, year = {2016}, }